Aktuellt
SENASTE
Redeye judges Fluoguide’s phase IIb trial with FG001 in high-grade glioma meeting its primary endpoint aligned with our expectations. Notably, FG001 seemed superior to white light, enabling the removal of additional cancer tissue in all treated patients. Reported results for the trial’s 5-ALA group were similar. So far, so good. We nudge up our valuation and will consider further changes once the company communicates how it plans to proceed with FG001’s clinical development.
LÄS MER
